Literature DB >> 10894837

Progression criteria for cancer antigen 15.3 and carcinoembryonic antigen in metastatic breast cancer compared by computer simulation of marker data.

G Sölétormos1, P Hyltoft Petersen, P Dombernowsky.   

Abstract

BACKGROUND: We investigated the utility of computer simulation models for performance comparisons of different tumor marker assessment criteria to define progression or nonprogression of metastatic breast cancer.
METHODS: Clinically relevant values for progressive cancer antigen 15.3 and carcinoembryonic antigen concentrations were combined with representative values for background variations in a computer simulation model. Fifteen criteria for assessment of longitudinal tumor marker data were obtained from the literature and computerized. Altogether, 7200 different patients, each based on 50 measurements, were simulated. With a sampling interval of 4 weeks, the monitoring period for each event was approximately 3.8 years.
RESULTS: Modulation of the background variation, the starting concentrations, and the cutoffs enabled identification of criteria that were robust against false-positive signals of progression.
CONCLUSIONS: The computer simulation model is a fast, effective, and inexpensive approach for comparing the diagnostic potential of assessment criteria during clinically relevant conditions of steady-state and progressive disease. The model systems can be used to generate tumor marker assessment criteria for a variety of malignancies and to compare and optimize their diagnostic performance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10894837

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  3 in total

1.  Making the most of a patient's laboratory data: optimisation of signal-to-noise ratio.

Authors:  Per Hyltoft Petersen
Journal:  Clin Biochem Rev       Date:  2005-11

Review 2.  Toward a Framework for Outcome-Based Analytical Performance Specifications: A Methodology Review of Indirect Methods for Evaluating the Impact of Measurement Uncertainty on Clinical Outcomes.

Authors:  Alison F Smith; Bethany Shinkins; Peter S Hall; Claire T Hulme; Mike P Messenger
Journal:  Clin Chem       Date:  2019-08-23       Impact factor: 8.327

3.  Modeling strategies to analyse longitudinal biomarker data: An illustration on predicting immunotherapy non-response in non-small cell lung cancer.

Authors:  Frederik A van Delft; Milou Schuurbiers; Mirte Muller; Sjaak A Burgers; Huub H van Rossum; Maarten J IJzerman; Hendrik Koffijberg; Michel M van den Heuvel
Journal:  Heliyon       Date:  2022-10-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.